SubHero Banner

Vonvendi® (von Willebrand factor [recombinant]) – New indication

January 31, 2022 - Takeda announced the FDA approval of Vonvendi (von Willebrand factor [recombinant]), for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy.

Download PDF